Back to mobile site

UBS Reiterates Buy Rating on Repligen (RGEN) as Incrementally Positive on Outlook

September 29, 2026 9:02 AM EDT Send to a Friend
UBS analyst Douglas Schenkel reiterated a Buy rating and $225.00 price target on Repligen (NASDAQ: RGEN).The analyst commented, "Our recent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login